Drug intelligence / Profile preview

Releaf

Development stage: Unknown
Lead developer: Phoilex
Modality: Small Molecules
Administration: Topical

Overview

Releaf is a non-specific term used for various products, devices, and applications. In the context of a drug, it refers to Phoilex Releaf Gel, a topical cannabidiol (CBD) product developed by Phoilex Ltd. for the potential therapeutic effects in treating atopic dermatitis. Clinical evaluation involves assessing its impact on skin hydration, soothing effects, itch relief, inflammation reduction, absorption, and overall improvement in skin condition.

Brand names: Phoilex Releaf Gel
Other names: Topical cannabidiolCBD gelcannabidiol

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on Releaf.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Releaf.

Explore the full profile